Phaseline

Companies › GC Biopharma

GC Biopharma: clinical trials, targets and expected readouts

8 active drug programs in 8 registered trials: 5 Phase 1, 3 Phase 3; Metabolic and endocrine, Infectious disease, Immunology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GC5107
Immune Globulin Intravenous (Human) - pooled human immunoglobulin replacement therapy
–Phase 3Primary Immune DeficiencyNov 2026
MG1111 (Barycela inj.)
Live attenuated varicella-zoster virus vaccine
–Phase 3Varicella (Chickenpox)Aug 2027
Undiluted I.V.-Hepabig inj (GC5103)
Hepatitis B immunoglobulin (anti-HBs antibody)
–Phase 3Hepatitis B–
GC4006A
COVID-19 preventive vaccine
–Phase 1COVID - 19May 2027
GC1123
Idursulfase-β (Hunter syndrome enzyme replacement therapy)
IDSPhase 1Mucopolysaccharidosis IIJun 2027
GC1130A
Recombinant human heparan N-sulfatase (rhHNS)
SGSHPhase 1Sanfilippo Syndrome Type AJun 2027
HM15421/GC1134A
unclear - Fabry disease modulator
–Phase 1Fabry DisesaseAug 2028
GC3111B
Vaccine immunization
–Phase 1Tetanus-diphtheria-acellular Pertussis (Tdap)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06997627GC3111BPhase 1Tetanus-diphtheria-acellular Pertussis (Tdap)OtherMay 2026
NCT05686759Undiluted I.V.-Hepabig inj (GC5103)Phase 3Hepatitis BInfectious diseaseJun 2026
NCT04565015GC5107Phase 3Primary Immune DeficiencyImmunologyNov 2026
NCT07728396GC4006APhase 1COVID - 19Infectious diseaseMay 2027
NCT05422482GC1123Phase 1Mucopolysaccharidosis IIMetabolic and endocrineJun 2027
NCT06567769GC1130APhase 1Sanfilippo Syndrome Type AMetabolic and endocrineJun 2027
NCT07054099MG1111 (Barycela inj.)Phase 3Varicella (Chickenpox)VaccinesAug 2027
NCT06858397HM15421/GC1134APhase 1Fabry DisesaseMetabolic and endocrineAug 2028

Targets

IDS (1) SGSH (1)

Companies with the same targets

Takeda Denali Therapeutics REGENXBIO Ultragenyx Pharmaceutical

Companies built like this

Xiamen Amoytop Biotech CSPC Ouyi Pharmaceutical Hudson Biotech Hangzhou Sciwind Biosciences BioMarin Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.